Sector News

India’s Strides to buy Australia, Mauritius drug assets from Aspen for $300 mln

May 21, 2015
Life sciences
(Reuters) – Indian drugmaker Strides Arcolab Ltd has agreed to buy businesses in Australia and Mauritius from South Africa’s Aspen Pharmacare Holdings Ltd , paying $300 million to expand its footprint in markets set for brisk growth.
 
For about A$380 million ($300 million), Strides is buying a generic drug operation in Australia that brought in sales of A$120 million in the year ended in June 2014, the firm said in a stock exchange filing on Thursday. (bit.ly/1LeoPOx)
 
The deal also covers the sale by Aspen’s Mauritius unit of a portfolio of six branded prescription drugs to Strides’ Singapore business. Strides, a major manufacturer of soft gelatin capsules, said it will also gain access to Aspen’s product pipeline that includes some “major product launches in the next six months”.
 
Australia’s pharmaceutical market is expected to grow to $32.1 billion by 2020 from $22.7 billion in 2013, according to market research firm Global Data, driven by rising health insurance cover and an increasing elderly population.
 
Invesors welcomed the news, sending Strides shares 5 percent higher in Mumbai at 0734 GMT, while the broader market was down 0.17 percent.
 
In its own statement, Aspen said the deals were in line with its existing strategy “to focus attention in areas where most value can be added”.
 
The moves are the latest in a series by Strides to streamline its portfio of assets. It bought Chennai, India-based drug ingredients maker Shasun Pharmaceuticals Ltd for $200 million last September, while in 2013 it sold its injectable drugs unit, Agila Specialties, to U.S. firm Mylan NV for about $1.6 billion.
 
Strides owned Ascent Pharmahealth Ltd in Australia until 2012, when it sold the business to U.S. firm Watson Pharmaceuticals Inc, now called Actavis plc. At the time, Strides said the deal was to sharpen its focus on high-margin, sterile injectable products.
 
Strides said the Australian business will operate under the Arrrow Pharmaceuticals brand and will sell both prescription and non-prescription products, Strides said.
 
The deals will be financed using internal reserves and debt, Strides said, and should be immediately accretive to its earnings per share. The company said it expects the deals to close by the end of the second quarter. ($1 = 1.2674 Australian dollars)
 
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair and Kenneth Maxwell)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend